Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 40%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 40%Moderate 1 · 20%High 0 · 0%

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · people with cancer with VTE receiving secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 1.11 [0.78, 1.59]
1 study · 284 participants
Moderate

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Recurrent VTE · people with cancer with VTE receiving secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in recurrent VTE compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.46 [0.16, 1.32]
1 study · 270 participants
Low

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Major bleeding · people with cancer with VTE receiving secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 1.11 [0.35, 3.56]
1 study · 270 participants
Low

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Minor bleeding ‐ not reported · people with cancer with VTE receiving secondary prophylaxis

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Health‐related quality of life ‐ not reported · people with cancer with VTE receiving secondary prophylaxis

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found